Bio Green Med Solution, Inc. 8-K

What Happened

• Bio Green Med Solution, Inc. (BGMS) filed an 8-K on June 22, 2026 reporting the results of its 2026 Annual Meeting held June 18, 2025. Shareholders re-elected two Class I directors, ratified the appointment of SFAI Malaysia Plt. as independent auditors for fiscal 2026, and approved an advisory vote on executive compensation.
• Directors re-elected for three-year terms expiring at the 2029 annual meeting: Dr. Satis Waran Nair Krishnan (3,807,082 votes for; 6,455 abstentions) and Inigo Angel Laurduraj (3,806,889 votes for; 6,648 abstentions). The filing states each nominee received a majority of votes cast and was elected.
• Shareholders ratified SFAI Malaysia Plt. as auditors with 4,321,612 votes for (78.3%), 13,017 against (0.2%) and 157 abstentions (0.003%). The advisory (non-binding) vote on executive compensation passed with 3,803,784 votes for (68.9%), 8,966 against (0.2%) and 787 abstentions (0.01%).

Key Details

• Meeting date (per filing): June 18, 2025; 8-K filed June 22, 2026.
• Directors re-elected: Dr. Satis Waran Nair Krishnan and Inigo Angel Laurduraj; terms expire 2029.
• Auditor ratification: SFAI Malaysia Plt. approved for 2026 fiscal year — 78.3% in favor.
• Executive compensation advisory: approved by ~68.9% of votes cast (non-binding).

Why It Matters

• Governance stability: Re-election of both Class I directors provides continuity on the board through 2029.
• Audit continuity: Ratifying SFAI Malaysia Plt. ensures the company has an auditor in place for fiscal 2026.
• Shareholder sentiment on pay: The advisory approval (~69% for) indicates majority support for the company’s disclosed executive compensation, though such votes are non-binding.
• For investors, these are routine corporate governance outcomes that affect board composition and oversight but do not in themselves change financial results.